Compare Monster Beverage Corp (MNST) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Monster Beverage Corp vs Summit Therapeutics Inc — how do they compare? Monster Beverage Corp trades at $43.64 (market cap $85.51B), while Summit Therapeutics Inc trades at $17.39 (market cap $13.71B). The key difference: Monster Beverage Corp is far larger — about 6.2× Summit Therapeutics Inc's market cap, and Monster Beverage Corp is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Monster Beverage Corp for 72 Days and Summit Therapeutics Inc for 16 Days on average.
| MNST | SMMT | |
|---|---|---|
Market Cap | $85.51B | $13.71B |
Volume | 8,569,709 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $49.97 | $26.38 |
52-Week Low | $33.16 | $12.43 |
Typical Hold Time | 72 Days | 16 Days |
Enterprise Value | $83.81B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monster Beverage (MNST) trades at $43.58, up 1.63% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $0.30, and maintains robust profitability with a net margin of 23.08% and zero long-term debt. Recent news highlights international sales growth of 35% in Q2 and a 1:2 stock split effective August 2026.
Outlook remains positive with a consensus price target of $98.22, implying significant upside, supported by international expansion and a debt-free balance sheet. Risks include competitive pressures, regulatory challenges in markets like India, and rich valuation multiples such as a P/E of 40.42. Analyst consensus is bullish with 52% buy ratings.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Monster Beverage Corp
Monster Beverage is a leader in the energy drink subsegment of the beverage industry. The Monster trademark anchors the portfolio, and notable offerings include Monster Energy and Monster Ultra. The firm has also started to incubate new trademarks for emerging enclaves of the energy space, like Reign in performance energy. It is primarily a brand owner, outsourcing most of its manufacturing processes to third-party copackers. It primarily uses the Coca-Cola bottling system for distribution after a strategic agreement in which Coke became Monster's largest shareholder (nearly 20%) and that also included the exchange of certain businesses between the two firms. Most of Monster's revenue is generated in the United States, though international geographies are increasing in the mix.
Read more on MNST →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
